The role of cytoreductive radical prostatectomy and lymph node dissection in bone‐metastatic prostate cancer: A population‐based study

Abstract

Abstract Backgrounds The role of cytoreductive radical prostatectomy (cRP) for bone‐metastatic prostate cancer (bmPCa) remains controversial. We aimed to figure out whether cRP and lymph node dissection (LND) can benefit bmPCa. Methods 11,271 PCa patients with bone metastatic burden from 2010 to 2019 were identified using SEER‐Medicare. Overall survival (OS) and cancer‐specific survival (CSS) rates were visualized using Kaplan–Meier plots. Multivariable Cox regression analyses were constructed to examine the effects of cRP and LND on survival, after stratifying to age, prostate specific antigen (PSA), clinical stages, Gleason score, metastatic burden, radiotherapy, and chemotherapy status. Results 317 PCa patients underwent cRP and cRP was increasingly performed for bmPCa from 2010 (2.2%) to 2019 (3.0%) (p < 0.05). In multi analyses, cRP was predisposed to a better OS or CSS in patients with age < 75, PSA < 98 ng/mL, bone‐only metastatic sites or patients not receiving chemotherapy (all p < 0.05). For the patients undergoing cRP, LND especially extended LND was associated with a better OS or CSS (all p < 0.05). Conclusions cRP might benefit OS or CSS in young patients with low PSA and bone‐only metastatic sites not receiving chemotherapy. And a clear OS or CSS benefit of LND especially extended LND was observed in patients undergoing cRP.

Keywords

• bone metastases
• cytoreductive radical prostatectomy
• lymph node dissection
• prostate cancer
• SEER‐Medicare
• survival analysis